The novel treatment of tirzepatide peptide represents a exciting development in the management of the condition. Unlike existing medications, tirzepatide targets two pathways – glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) – resulting in improved sugar con